Key Performance
More- Earnings Score: 53
- Momentum Score: 98
- True Yield: N/A
- Financial Health Score: 25
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons to Revolution Medicines and placed the company at risk of patent and trade secret violations. Investors who purchased Erasca securities between January 14, 2025 and April 26, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.
06/23/2026, 12:00 PM • GlobeNewswire
Erasca, Inc. faces a securities fraud class action lawsuit after disclosing a patent infringement allegation from Revolution Medicines on April 27, 2026, followed by a patient death in its ERAS-0015 Phase 1 trial on April 28, 2026. The stock plummeted 48.3% on April 28 after the death disclosure. The lawsuit alleges the company made materially false statements about ERAS-0015's preclinical data and failed to disclose material risks. The deadline to file a lead plaintiff motion is August 10, 2026.
06/22/2026, 12:57 PM • GlobeNewswire
Erasca, Inc. faces a securities class action lawsuit alleging that the company and its executives made false statements about its lead drug candidate ERAS-0015. The lawsuit claims preclinical data was based on improper comparisons and lacked reasonable basis. On April 27, 2026, Erasca disclosed a patent infringement assertion from Revolution Medicines and reported a patient death in Phase I trials, causing the stock to plummet nearly 59% over two trading days. Investors with substantial losses can seek appointment as lead plaintiff by August 10, 2026.
06/20/2026, 11:30 AM • GlobeNewswire
Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. The deadline to seek lead plaintiff status is August 10, 2026.
06/20/2026, 8:40 AM • GlobeNewswire
Erasca, Inc. (NASDAQ: ERAS) stock plummeted 48% ($9.25) after the company disclosed a patient death following ERAS-0015 treatment and faced patent infringement accusations from Revolution Medicines. The company allegedly misled investors about the drug's efficacy and intellectual property protection. The disclosures wiped out $2.8 billion in market capitalization, prompting a securities class action lawsuit covering the period from January 14, 2025 to April 26, 2026.
06/18/2026, 1:43 PM • GlobeNewswire
A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. On April 28, 2026, Erasca disclosed a patent infringement letter from Revolution Medicines, causing the stock to plummet 48% from $19.15 to $9.90 per share.
06/17/2026, 7:08 PM • GlobeNewswire
Rosen Law Firm has filed a class action lawsuit against Erasca, Inc. on behalf of investors who purchased common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes. Investors who wish to serve as lead plaintiff must file by August 10, 2026.
06/15/2026, 10:38 PM • GlobeNewswire
Erasca, Inc. (NASDAQ: ERAS) stock plummeted 48% ($9.25) after the company disclosed a patient death following ERAS-0015 treatment and faced patent infringement accusations from Revolution Medicines. The company allegedly misled investors about the drug's efficacy comparisons and intellectual property protection. The disclosures wiped out $2.8 billion in market capitalization, prompting a securities class action lawsuit covering the period from January 14, 2025 to April 26, 2026.
06/15/2026, 8:51 PM • GlobeNewswire
A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit stems from a patent infringement letter received from Revolution Medicines on April 28, 2026, which triggered a 48% stock price decline from $19.15 to $9.90 per share. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 are encouraged to contact the law firm.
06/11/2026, 5:54 PM • GlobeNewswire
Block & Leviton LLP filed a class action lawsuit against Erasca, Inc. and its executives for allegedly making false and misleading statements about its oncology drug candidate ERAS-0015 between January 2025 and April 2026. The company allegedly touted the drug as 'best-in-class' with superior results compared to a competitor's drug while failing to disclose improper comparisons and patent disputes. Following disclosures of patent infringement accusations and clinical data showing a patient death, Erasca's stock fell over 45%. Investors who purchased stock during the class period may seek damages.
06/10/2026, 4:56 PM • GlobeNewswire
Revolution Medicines announced positive Phase 3 RASolute 302 trial results for daraxonrasib, an oral RAS(ON) inhibitor, in previously treated metastatic pancreatic cancer. The drug demonstrated a 60% reduction in death risk and doubled median overall survival to 13.2 months compared to 6.6 months with standard chemotherapy, with a manageable safety profile. Results were presented at ASCO 2026 and published in The New England Journal of Medicine.
05/31/2026, 8:06 AM • GlobeNewswire
Law firm Bragar Eagel & Squire is investigating Erasca, Inc. following a patent infringement allegation from Revolution Medicines regarding the company's ERAS-0015 drug candidate. The disclosure triggered a significant stock price decline of approximately 48%, dropping from $19.15 to $9.90 per share on April 28, 2026. The firm is seeking stockholders who suffered losses to discuss potential legal claims.
05/19/2026, 6:53 PM • GlobeNewswire
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Revolution Medicines' experimental pancreatic cancer drug daraxonrasib has generated significant demand from cancer centers following FDA approval of its expanded access program in May. The Phase 3 RASolute 302 trial showed the drug doubled overall survival to 13.2 months versus 6.7 months for standard chemotherapy. However, the company faces operational challenges managing the compassionate use process, and RVMD stock declined 3.47% despite the positive clinical results.
05/15/2026, 11:47 AM • Benzinga
ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations following the company's disclosure on April 28, 2026, that it received a patent infringement letter from Revolution Medicines regarding its ERAS-0015 drug candidate, along with trade secret misappropriation allegations. The announcement triggered a 48.3% stock price decline on the same day.
05/10/2026, 7:29 PM • GlobeNewswire
Revolution Medicines announced the publication of Phase 1/2 clinical trial data for daraxonrasib in the New England Journal of Medicine, showing promising antitumor activity and durable responses in previously treated metastatic RAS mutant pancreatic cancer. The data supported initiation of the Phase 3 RASolute 302 trial, which recently reported unprecedented overall survival benefits compared to standard chemotherapy.
05/06/2026, 6:00 PM • GlobeNewswire
